LIN vs RGNX · P/E 34, rev $18.07B vs rev $114.4M
Linde plc Ordinary Shares (LIN) versus Regenxbio Inc (RGNX) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. RGNX currently screens at market cap $440.4M.
Not investment advice. Open the LIN and RGNX stock pages for the full models.
Not investment advice.